A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Sponsor
Novo Nordisk A/S
Study ID
NCT06049329
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • NNC0487-0111 — DRUG
    Participants will get one tablet to swallow at the same time of the day.
  • Placebo (NNC0487-0111) — DRUG
    Participants will get one tablet to swallow at the same time of the day.

Study Details

The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.

Key Dates

Start date
Sep 14, 2023
Status verified
Mar 2025
Primary completion
Dec 15, 2023
Completion
Dec 15, 2023

Study Design

Enrollment
36 participants (actual)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC0487-0111
    Once-daily oral administration - 1 of 3 different doses
  • Placebo Comparator: Placebo
    Once-daily oral administration - 1 of 3 different doses

Primary Outcome Measure

Number of treatment emergent adverse events (TEAE) [ Time Frame: From pre-dose on Day 1 until completion of the end of study visit Day 31 ]

Related Studies